Loss of Expression of Transforming Growth Factor Beta in Skin and Skin Tumors is Associated with Hyperproliferation and a High Risk for Malignant Conversion

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1993 Jul 1

PMID 7687059

Citations 47

Authors

A B Glick

A B Kulkarni

T Tennenbaum

H Hennings

K C Flanders

M OReilly

M B Sporn

S Karlsson

S H Yuspa

Affiliations

Soon will be listed here.

Abstract

Mouse skin carcinomas arise from a small subpopulation of benign papillomas with an increased risk of malignant conversion. These papillomas arise with limited stimulation by tumor promoters, appear rapidly, and do not regress, suggesting that they differ in growth properties from the majority of benign tumors. The transforming growth factor beta (TGF-beta) proteins are expressed in the epidermis and are growth inhibitors for mouse keratinocytes in vitro; altered TGF-beta expression could influence the growth properties of high-risk papillomas. Normal epidermis, tumor promoter-treated epidermis, and skin papillomas at low risk for malignant conversion express TGF-beta 1 in the basal cell compartment and TGF-beta 2 in the suprabasal strata. In low-risk tumors, 90% of the proliferating cells are confined to the basal compartment. In contrast, the majority of high-risk papillomas are devoid of both TGF-beta 1 and TGF-beta 2 as soon as they arise; these tumors have up to 40% of the proliferating cells in the suprabasal layers. Squamous cell carcinomas are also devoid of TGF-beta, suggesting that they arise from the TGF-beta-deficient high-risk papillomas. In some high-risk papillomas, TGF-beta 1 loss can occur first and correlates with basal cell hyperproliferation, while TGF-beta 2 loss correlates with suprabasal hyperproliferation. Similarly, TGF-beta 1-null transgenic mice, which express wild-type levels of TGF-beta 2 in epidermis but no TGF-beta 1 in the basal layer, have a hyperproliferative basal cell layer without suprabasal proliferation. In tumors, loss of TGF-beta is controlled at the posttranscriptional level and is associated with expression of keratin 13, a documented marker of malignant progression. These results show that TGF-beta expression and function are compartmentalized in epidermis and epidermal tumors and that loss of TGF-beta is an early, biologically relevant risk factor for malignant progression.

Citing Articles

TGF-β signaling in health, disease, and therapeutics.

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.

PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.

Serum-Induced Proliferation of Human Cardiac Stem Cells Is Modulated via TGFβRI/II and SMAD2/3.

Schmidt K, Hoving A, Kiani Zahrani S, Trevlopoulou K, Kaltschmidt B, Knabbe C Int J Mol Sci. 2024; 25(2).

PMID: 38256034 PMC: 10815425. DOI: 10.3390/ijms25020959.

TGFβ1 regulates HRas-mediated activation of IRE1α through the PERK-RPAP2 axis in keratinocytes.

Mogre S, Blazanin N, Walsh H, Ibinson J, Minnich C, Hu C Mol Carcinog. 2022; 61(10):958-971.

PMID: 35975910 PMC: 9486931. DOI: 10.1002/mc.23453.

Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Pena-Romero A, Orenes-Pinero E Cancers (Basel). 2022; 14(7).

PMID: 35406451 PMC: 8996887. DOI: 10.3390/cancers14071681.

Targeted deletion of TGFβ1 in basal keratinocytes causes profound defects in stratified squamous epithelia and aberrant melanocyte migration.

Chalmers F, Dusold J, Shaik J, Walsh H, Glick A Dev Biol. 2022; 485:9-23.

PMID: 35227671 PMC: 8969113. DOI: 10.1016/j.ydbio.2022.02.009.

References

Fitzpatrick D, Denhez F, Kondaiah P, Akhurst R . Differential expression of TGF beta isoforms in murine palatogenesis. Development. 1990; 109(3):585-95. DOI: 10.1242/dev.109.3.585. View

Flanders K, Cissel D, Mullen L, Danielpour D, Sporn M, Roberts A . Antibodies to transforming growth factor-beta 2 peptides: specific detection of TGF-beta 2 in immunoassays. Growth Factors. 1990; 3(1):45-52. DOI: 10.3109/08977199009037501. View

Kane C, Hebda P, Mansbridge J, HANAWALT P . Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J Cell Physiol. 1991; 148(1):157-73. DOI: 10.1002/jcp.1041480119. View

Huitfeldt H, Heyden A, Clausen O, Thrane E, Roop D, Yuspa S . Altered regulation of growth and expression of differentiation-associated keratins in benign mouse skin tumors. Carcinogenesis. 1991; 12(11):2063-7. DOI: 10.1093/carcin/12.11.2063. View

Missero C, Ramon Y Cajal S, Dotto G . Escape from transforming growth factor beta control and oncogene cooperation in skin tumor development. Proc Natl Acad Sci U S A. 1991; 88(21):9613-7. PMC: 52768. DOI: 10.1073/pnas.88.21.9613. View

Wu S, Theodorescu D, Kerbel R, WILLSON J, Mulder K, Humphrey L . TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol. 1992; 116(1):187-96. PMC: 2289262. DOI: 10.1083/jcb.116.1.187. View

Kulkarni A, Huh C, Becker D, Geiser A, Lyght M, Flanders K . Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993; 90(2):770-4. PMC: 45747. DOI: 10.1073/pnas.90.2.770. View

Pai S, Steele V, Nettesheim P . Neoplastic transformation of primary tracheal epithelial cell cultures. Carcinogenesis. 1983; 4(4):369-74. DOI: 10.1093/carcin/4.4.369. View

Balmain A, Pragnell I . Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature. 1983; 303(5912):72-4. DOI: 10.1038/303072a0. View

10.

Hennings H, Shores R, Wenk M, Spangler E, Tarone R, Yuspa S . Malignant conversion of mouse skin tumours is increased by tumour initiators and unaffected by tumour promoters. Nature. 1983; 304(5921):67-9. DOI: 10.1038/304067a0. View

11.

Balmain A, Ramsden M, Bowden G, Smith J . Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature. 1984; 307(5952):658-60. DOI: 10.1038/307658a0. View

12.

Hennings H, Shores R, Mitchell P, Spangler E, Yuspa S . Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis. 1985; 6(11):1607-10. DOI: 10.1093/carcin/6.11.1607. View

13.

Shipley G, Pittelkow M, Wille Jr J, Scott R, Moses H . Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. Cancer Res. 1986; 46(4 Pt 2):2068-71. View

14.

Shivers B, Schachter B, Pfaff D . In situ hybridization for the study of gene expression in the brain. Methods Enzymol. 1986; 124:497-510. DOI: 10.1016/0076-6879(86)24036-7. View

15.

Oberhammer F, Pavelka M, Sharma S, Tiefenbacher R, Purchio A, Bursch W . Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc Natl Acad Sci U S A. 1992; 89(12):5408-12. PMC: 49301. DOI: 10.1073/pnas.89.12.5408. View

16.

Yanagihara K, Tsumuraya M . Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res. 1992; 52(14):4042-5. View

17.

Kim S, Park K, Koeller D, Kim K, Wakefield L, Sporn M . Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem. 1992; 267(19):13702-7. View

18.

Fowlis D, Flanders K, Duffie E, Balmain A, Akhurst R . Discordant transforming growth factor beta 1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ. 1992; 3(2):81-91. View

19.

Lee E, Punnonen K, Cheng C, Glick A, Dlugosz A, Yuspa S . Analysis of phospholipid metabolism in murine keratinocytes transformed by the v-ras oncogene: relationship of phosphatidylinositol turnover and cytokine stimulation to the transformed phenotype. Carcinogenesis. 1992; 13(12):2367-73. DOI: 10.1093/carcin/13.12.2367. View

20.

Hennings H, Spangler E, Shores R, Mitchell P, DEVOR D, Shamsuddin A . Malignant conversion and metastasis of mouse skin tumors: a comparison of SENCAR and CD-1 mice. Environ Health Perspect. 1986; 68:69-74. PMC: 1474248. DOI: 10.1289/ehp.866869. View